Influenza-induced acute respiratory distress syndrome during the 2010-2016 seasons: bacterial co-infections and outcomes by virus type and subtype.


Journal

Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases
ISSN: 1469-0691
Titre abrégé: Clin Microbiol Infect
Pays: England
ID NLM: 9516420

Informations de publication

Date de publication:
Jul 2020
Historique:
received: 21 11 2019
revised: 22 02 2020
accepted: 07 03 2020
pubmed: 25 3 2020
medline: 29 1 2021
entrez: 25 3 2020
Statut: ppublish

Résumé

We aimed to describe bacterial co-infections and acute respiratory distress (ARDS) outcomes according to influenza type and subtype. A retrospective observational study was conducted from 2012 to 2016 in patients admitted to the respiratory intensive care unit (ICU) of Marseille university hospital for influenza-induced ARDS. Microbiological investigations, including multiplex molecular respiratory panel testing and conventional bacteriological cultures, were performed as part of the routine ICU care on the bronchoalveloar lavage collected at admission. Bacterial co-infections, ICU mortality and respiratory function were investigated according to virus type and subtype. Among the 45 ARDS patients included, A(H1N1)pdm09 was the most frequent influenza virus identified (28/45 A(H1N1)pdm09, eight out of 45 A(H3N2) and nine out of 45 influenza B). Bacterial co-infections involving a total of 23 bacteria were diagnosed in 16/45 patients (36%). A(H1N1)pdm09 patients presented fewer bacterial co-infections (17.9% vs. 50.0% for A(H3N2) patients and 77.8% for B patients; p < 0.01). Overall, mortality at 90 days post admission was 33.3% (15/45), and there was no significant difference between influenza type and subtype. The need for extracorporeal membrane oxygenation was more frequent for A(H1N1)pdm2009 (20/28, 71.4%) and B patients (7/9, 77.8%) than the A(H3N2) subtype (1/8, 12.5%; p < 0.01). A(H1N1)pdm09-ARDS patients were associated with fewer ventilation-free days at day 28 (median (IQR): 0 (0-8) days) compared with other influenza-ARDS patients (15 (0-25) days, p < 0.05). In a population of influenza-induced ARDS, A(H1N1)pdm09 was associated with fewer bacterial co-infections but poorer respiratory outcomes. These data underline the major role of A(H1N1)pdm09 subtype on influenza disease severity.

Identifiants

pubmed: 32205296
pii: S1198-743X(20)30152-X
doi: 10.1016/j.cmi.2020.03.010
pii:
doi:

Types de publication

Journal Article Observational Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

947.e1-947.e4

Informations de copyright

Copyright © 2020 European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd. All rights reserved.

Auteurs

A Bal (A)

Laboratoire de Virologie, Institut des Agents Infectieux, Groupement Hospitalier Nord, Hospices Civils de Lyon, Lyon, France; University of Lyon, Université Lyon 1, CIRI, Inserm U1111 CNRS UMR5308, Virpath, Lyon, France.

J S Casalegno (JS)

Laboratoire de Virologie, Institut des Agents Infectieux, Groupement Hospitalier Nord, Hospices Civils de Lyon, Lyon, France; University of Lyon, Université Lyon 1, CIRI, Inserm U1111 CNRS UMR5308, Virpath, Lyon, France.

C Melenotte (C)

Aix Marseille University, IRD, AP-HM, MEPHI, IHU Méditerranée Infection, Marseille, France.

F Daviet (F)

Service de Médecine Intensive - Réanimation, APHM, Hôpital Nord, Marseille, France; CEReSS - Centre for Studies and Research on Health Services and Quality of Life EA3279, Aix-Marseille University, France.

L Ninove (L)

Unité des Virus Emergents (UVE: Aix- Marseille Univ., IRD 190, INSERM 1207, IHU Méditerranée Infection), Marseille, France.

S Edouard (S)

Aix Marseille University, IRD, AP-HM, MEPHI, IHU Méditerranée Infection, Marseille, France.

F Morfin (F)

Laboratoire de Virologie, Institut des Agents Infectieux, Groupement Hospitalier Nord, Hospices Civils de Lyon, Lyon, France; University of Lyon, Université Lyon 1, CIRI, Inserm U1111 CNRS UMR5308, Virpath, Lyon, France.

M Valette (M)

Laboratoire de Virologie, Institut des Agents Infectieux, Groupement Hospitalier Nord, Hospices Civils de Lyon, Lyon, France; University of Lyon, Université Lyon 1, CIRI, Inserm U1111 CNRS UMR5308, Virpath, Lyon, France.

X De Lamballerie (X)

Unité des Virus Emergents (UVE: Aix- Marseille Univ., IRD 190, INSERM 1207, IHU Méditerranée Infection), Marseille, France.

B Lina (B)

Laboratoire de Virologie, Institut des Agents Infectieux, Groupement Hospitalier Nord, Hospices Civils de Lyon, Lyon, France; University of Lyon, Université Lyon 1, CIRI, Inserm U1111 CNRS UMR5308, Virpath, Lyon, France.

L Papazian (L)

Service de Médecine Intensive - Réanimation, APHM, Hôpital Nord, Marseille, France; CEReSS - Centre for Studies and Research on Health Services and Quality of Life EA3279, Aix-Marseille University, France.

A Nougairède (A)

Unité des Virus Emergents (UVE: Aix- Marseille Univ., IRD 190, INSERM 1207, IHU Méditerranée Infection), Marseille, France.

S Hraiech (S)

Service de Médecine Intensive - Réanimation, APHM, Hôpital Nord, Marseille, France; CEReSS - Centre for Studies and Research on Health Services and Quality of Life EA3279, Aix-Marseille University, France. Electronic address: sami.hraiech@ap-hm.fr.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH